<DOC>
	<DOCNO>NCT00241189</DOCNO>
	<brief_summary>This study determine safety immunosuppressive rapamycin patient systemic sclerosis diffuse cutaneous scleroderma . The effect ( good bad ) compare another group systemic sclerosis patient receive methotrexate</brief_summary>
	<brief_title>Rapamycin v Methotrexate Diffuse SSc</brief_title>
	<detailed_description>Systemic sclerosis ( SSc ) disorder characterize overproduction deposition collagen skin visceral organ , abnormality microcirculation , autoimmunity . Patients develop extensive skin thickening ( diffuse cutaneous scleroderma ) usually within first 5 year . In add tion significant risk early death , severe involvement heart ( 10 % ) , lung ( 15 % ) kidney ( 15-20 % ) loss functional capacity ( moderate severe disability 50 % within first year ) . yet proven cure treatment prevents heart , lung kidney damage , prevents disability improve survival . In previsou study , treat 10 SSc patient diffuse cutaneous scleroerma cyclosporin A ( CsA ) , agent suppresses immune response reduce production pro-inflammatory cytokine , interleukin-2 ( IL-2 ) . Significant improvement skin thicken note 6 10 SSc patient . Unfortuantely , significant reduction kidney function and/or new onset high blood pressure occur 8 10 . This frequency degree adverse event ina population already risk kidney failure high blood pressure unacceptable . More recently immunosuppressive agent little kidney toxicity , rapamycin , find block effect pro-inflammatory cytokine cyclosporin ( IL-2 ) transplant patient part immunosuppressive action . Since improvement skin thicken see patient receive CsA , postulate block effect IL-2 rapamycin also result improvement skin thicken SSc patient extensive skin thickening . There grow evidence ( work work others ) soften thick skin diffuse SSc associate improvement hand function , joint mobility , arthritis sign , overall functional ability , survival . The effectiveness another immunosuppressive , methotrexate , compare placebo ( dummy ) two SSc study combine total 100 patient estensive skin thickening . In study trend great soften thick scleroderma skin . In one study great sense general well also noted methotrexate group study physician global assessment improve great extent methotrexate group . Because suggestion benefit methotrexate , present trial evaluate rapamycin compare methotrexte . During 48 week period rapamycin methotrexate take randomly assign ( 9 patient arm total 18 patient ) . Over 48 week , status patient ' scleroderma assess simple validated technique , include simple palpation skin ass skin thickness ; lung function text , electrocardiogram chest x-ray assess heart lungp ; blood pressure serum creatinine ass kidney ; 3 questionnaire ( complete patient ) ass function , quality life shortness breath ; CBC , chemistry rapamycin level assess safety . Statistical analysis course two treatment group help u determine whether rapamycin excessive toxicity whether suggestion efficacy rapamycin .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Satisfy American College Rheumatology classification criterion systemic sclerosis Have skin thicken proximal elbow and/or knee ( diffuse scleroderma ) Cutaneous involvement le 5 year onset first nonRaynaud 's manifestation Severe intractable malabsorption Chronic debilitation underlie disease Off putative disease modify therapy one month prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Methotrexate</keyword>
</DOC>